| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | Ianalumab - (VAYHIT3) | Primary immune thrombocytopenia | Phase 2 | Ongoing | Intravenous | Hematology |
| Novartis AG | Votoplam - (PIVOT-HD) | Huntington's disease | Phase 2 | Data Released | Oral | Neurology |
| Novartis AG | Ianalumab - (AMBER) | Autoimmune hepatitis | Phase 2 | Ongoing | Subcutaneous | Immunology |
| Novartis AG | XXB750 | Heart failure | Phase 2 | Trial Discontinued | Intravenous | Cardiology |
| Novartis AG | Kisqali - (RIGHT Choice) | HR+/HER2‚àí metastatic breast cancer | Phase 2 | Data Released | Oral | Oncology |
| Novartis AG | LXH254 combos | Metastatic Melanoma | Phase 2 | oral | Oncology | |
| Novartis AG | FCR001 | COVID-19 in living donor kidney transplant (LDKT) patients | Phase 2 | Ongoing | Intravenous | COVID-19 |
| Novartis AG | Canakinumab (ACZ885) - (CANOPY-N) | Non-small cell lung cancer (NSCLC) neoadjuvant setting (before surgery) | Phase 2 | Subcutaneous | Oncology |